ביונד ביולוג'יקס

Biond's leading development programs include BND-22, a multi-cell checkpoint inhibitor targeting ILT2, and BND-67, a novel agent developed for overcoming PD-1 blockade resistance by targeting soluble CD28; an immune evasion mechanism discovered by Biond scientists. The company is also developing BND-35 – an ILT3 blocking antibody, that targets suppressive myeloid cells in the tumor microenvironment. In addition to its pipeline of immunotherapy agents, Biond is developing INspire – an innovative technological platform that enables the intracellular delivery of protein therapeutics, such as antibodies or enzymes, into cells.

Pharmaceutical & Biotech companies, Venture capital, Private investors.

Tehila Ben-Moshe - CEO & Co-Founder

Avidor Shulman - CTO

Ori Shilo - CFO & Co-Founder